Travoprost intraocular implant - Glaukos

Drug Profile

Travoprost intraocular implant - Glaukos

Alternative Names: iDose Travoprost; Travoprost implant - Glaukos

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dose medical corporation
  • Developer Glaukos Corporation
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma

Most Recent Events

  • 10 Jan 2018 Interim efficacy and adverse events data from a phase II trial in Glaucoma released by Glaukos Corporation
  • 10 Jan 2018 Glaukos intends to initiate phase III trials in Glaucoma in USA and World in the first half of 2018
  • 17 Dec 2017 Glaukos completes enrolment in its phase II trial for Glaucoma in USA, before December 2017 (NCT02754596)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top